September 2010 Approvals
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class
Chart lists efficacy supplements and labeling supplements selected by the editors of "Pharmaceuticals Approvals Monthly." This is not a comprehensive list of all supplemental approvals.